Outside Publication

ESG Trends and Practices in the Biopharma Industry, Pharmaceutical Executive

June 14, 2021

Partner Carl Valenstein authored a column for Pharmaceutical Executive about environmental, social, and governance (ESG) trends in the biopharma sector. The piece notes that as biopharma companies step up their ESG initiatives, “[l]egal counsel should be involved early on to ensure that ESG disclosures are properly validated and qualified.” The column also addresses how larger companies “have used their extensive resources and capital to create committees and teams responsible for assessing, improving, and in many cases creating and implementing new and effective ESG practices and initiatives,” while “small biopharma companies should ensure that the language used in their reports can be easily compared to what their peers are saying.”

Read the full Pharmaceutical Executive article >>